Coventry, UK, 10th December 2020 / Sciad Newswire / NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director. NanoSyrinx is an early-stage biotechnology company using synthetic biology approaches to develop a completely novel platform for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells. Dr Dancer has over 30 years’ experience in business development across biotech, pharma and agrochemicals and her experience will help to drive NanoSyrinx’s ongoing fundraising activities and ambitious growth plans.
Dr Dancer is a highly experienced business leader with previous roles including Chief Business Officer at F-star, Vice President of Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)). Jane holds an MA and Ph.D. in Natural Sciences from the University of Cambridge and an MBA from The Cambridge Judge Business School. She has an active role in advising companies on business development and strategy and is currently on the board of Spirea, PharmEnable, Macomics and Chair of the Sir Richard Stapley Educational Trust.
Dr Joe Healey, CEO of NanoSyrinx, commented, “We’re delighted to welcome Jane to our board as Non-Executive Director. Her wealth of experience in business development and company growth will provide valuable insights to guide and support our growth plans and drive the development of our innovative platform technology. I look forward to working with Jane and benefiting from her extensive knowledge.”
NanoSyrinx is developing a fully customisable genetic platform that selectively delivers peptide and protein payloads – including functional gene editing enzymes and nucleases – directly to the cytosol of targeted cells. The system was first identified by the Waterfield Lab based at Warwick Medical School at the University of Warwick. NanoSyrinx Ltd was founded in 2020 following the completion of an extensive international market validation exercise under the ICURe programme, funded by Innovate UK. In September 2020, the Company announced a pre-seed funding round led by M Ventures with contributions from BioCity and UK Innovation & Science Seed Fund (UKI2S).
Notes to Editors
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. NanoSyrinx was co-founded in 2020 by Dr Healey, Dr Waterfield and Dr Hapeshi to commercialise the team’s research at the University of Warwick’s Medical School. Dr Stephen Taylor, ex SVP at Fujifilm Diosynth, has joined the company as Executive Chair.
For more information, visit https://www.nanosyrinx.com/
About M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact the company's core business areas. From its headquarters in Amsterdam and offices in the US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. M Ventures has a significant focus on early stage investing and company creation including the creation of spin-offs to leverage the company's science and technology base. For more information, visit www.m-ventures.com
For further information, please contact:
Dr Joe Healey
Media Relations – Sciad Communications
Juliette Craggs / Richard Anderson
T: +44(0)20 3405 7892